Main content

    Health Information

    Vinpocetine

    Vinpocetine

    Uses

    What Are Star Ratings?

    Our proprietary ?Star-Rating? system was developed to help you easily understand the amount of scientific support behind each supplement in relation to a specific health condition. While there is no way to predict whether a vitamin, mineral, or herb will successfully treat or prevent associated health conditions, our unique ratings tell you how well these supplements are understood by the medical community, and whether studies have found them to be effective for other people.

    For over a decade, our team has combed through thousands of research articles published in reputable journals. To help you make educated decisions, and to better understand controversial or confusing supplements, our medical experts have digested the science into these three easy-to-follow ratings. We hope this provides you with a helpful resource to make informed decisions towards your health and well-being.

    3 Stars Reliable and relatively consistent scientific data showing a substantial health benefit.

    2 Stars Contradictory, insufficient, or preliminary studies suggesting a health benefit or minimal health benefit.

    1 Star For an herb, supported by traditional use but minimal or no scientific evidence. For a supplement,little scientific support.

    This supplement has been used in connection with the following health conditions:

    Used for Why
    2 Stars
    Age-Related Cognitive Decline
    30 to 60 mg daily
    Learn More

    A double-blind trial found both 30 mg and 60 mg per day of vinpocetine improved symptoms of dementia in patients with various brain diseases.1 Another double-blind trial gave 30 mg per day of vinpocetine for one month, followed by 15 mg per day for an additional two months, to people with dementia associated with hardening of the arteries of the brain, and significant improvement in several measures of memory and other cognitive functions was reported.2 Other double-blind trials have reported similar effects of vinpocetine in people with some types of dementia or age-related cognitive decline.3 , 4 However, a study of Alzheimer patients in the United States found vinpocetine given in increasing amounts from 30 mg to 60 mg per day over the course of a year neither reversed nor slowed the decline in brain function measured by a number of different tests.5

    2 Stars
    Stroke
    30 to 60 mg per day taken with food
    Learn More

    Vinpocetine given by intravenous injection has been reported to improve some biochemical measures of brain function in stroke patients.6 , 7 A controlled trial found intravenous vinpocetine given within 72 hours of a stroke reduced some of the losses in brain function that typically follow a stroke.8 However, the reliability of human stroke research using vinpocetine has been questioned,9 , 10 and more double-blind trials are needed. No studies using oral vinpocetine for treating acute strokes have been published.

    2 Stars
    Urinary Incontinence (urge incontinence )
    5 mg three times daily for two weeks, then 10 mg three times daily for two weeks
    Learn More
    Vinpocetine is a semisynthetic derivative of vincamine, one of the major active compounds found in periwinkle. In a small, preliminary study, men and women with urge incontinence were given 5 mg of vinpocetine three times daily for two weeks, then 10 mg three times daily for an additional two weeks. About half of the subjects reported reduced symptoms of urge incontinence and also improved in laboratory measures of bladder muscle control.11 However, a small, double-blind trial found improvement in only one of several measures of urge incontinence.12 More double blind trials are needed to confirm these findings.
    2 Stars
    Vertigo
    15 mg daily
    Learn More

    A preliminary trial showed that 15 mg per day of vinpocetine had a moderate or greater effect on reducing the signs and symptoms of vertigo in 77% of patients with this condition.13 Other preliminary reports exist describing benefits of vinpocetine for vertigo and other symptoms of inner ear disorders,14 but controlled research is needed to evaluate these claims.

    1 Star
    Retinopathy
    Refer to label instructions
    Learn More

    Preliminary studies have reported improved vision in people with various diseases of the retina who took 45 mg per day of vinpocetine .15

    How It Works

    How to Use It

    Research has typically used 30 to 60 mg per day of vinpocetine. Taking vinpocetine with food appears to dramatically improve its absorption. 16

    Where to Find It

    Vinpocetine is synthesized from vincamine, a constituent of the leaves of Vinca minor (lesser periwinkle)

    Possible Deficiencies

    Vinpocetine is not an essential nutrient, so no deficiencies are possible.

    Interactions

    Interactions with Supplements, Foods, & Other Compounds

    Vinpocetine has blood-thinning effects,17 which suggests that people with bleeding disorders or who are taking anticoagulant or other blood-thinning medications should consult a doctor before taking vinpocetine. However, one study found no such interaction between vinpocetine and the anticoagulant drug warfarin. 18

    Interactions with Medicines

    Certain medicines interact with this supplement.

    Types of interactions: Beneficial Adverse Check

    Replenish Depleted Nutrients

    • none

    Reduce Side Effects

    • none

    Support Medicine

    • Alprazolam

      In a preliminary trial, an extract of periwinkle called vinpocetine was shown to produce minor improvements in short-term memory among people taking flunitrazepam, a benzodiazepine.19 Further study is needed to determine if vinpocetine would be a helpful adjunct to use of benzodiazepines, or alprazolam specifically.

      The interaction is supported by preliminary,weak, fragmentary, and/or contradictory scientific evidence.
    • Chlordiazepoxide

      In a preliminary trial, an extract of periwinkle called vinpocetine was shown to produce minor improvements in short-term memory among people taking flunitrazepam, a benzodiazepine.20 Further study is needed to determine if vinpocetine would be a helpful adjunct to use of benzodiazepines.

      The interaction is supported by preliminary,weak, fragmentary, and/or contradictory scientific evidence.
    • Clonazepam

      In a preliminary trial, an extract of periwinkle called vinpocetine was shown to produce minor improvements in short-term memory among people taking flunitrazepam, a benzodiazepine.21 Further study is needed to determine if vinpocetine would be a helpful adjunct to use of benzodiazepines.

      The interaction is supported by preliminary,weak, fragmentary, and/or contradictory scientific evidence.
    • Clorazepate

      In a preliminary trial, an extract of periwinkle called vinpocetine was shown to produce minor improvements in short-term memory among people taking flunitrazepam, a benzodiazepine.22 Further study is needed to determine if vinpocetine would be a helpful adjunct to use of benzodiazepines, or clorazepate specifically.

      The interaction is supported by preliminary,weak, fragmentary, and/or contradictory scientific evidence.
    • Diazepam

      In a preliminary trial, an extract of periwinkle called vinpocetine was shown to produce minor improvements in short-term memory among people taking flunitrazepam, a benzodiazepine.23 Further study is needed to determine if vinpocetine would be a helpful adjunct to use of benzodiazepines.

      The interaction is supported by preliminary,weak, fragmentary, and/or contradictory scientific evidence.
    • Estazolam

      In a preliminary trial, an extract of periwinkle called vinpocetine was shown to produce minor improvements in short-term memory among people taking flunitrazepam, a benzodiazepine.24 Further study is needed to determine if vinpocetine would be a helpful adjunct to use of benzodiazepines.

      The interaction is supported by preliminary,weak, fragmentary, and/or contradictory scientific evidence.
    • Lorazepam

      In a preliminary trial, an extract of periwinkle called vinpocetine was shown to produce minor improvements in short-term memory among people taking flunitrazepam, a benzodiazepine.25 Further study is needed to determine if vinpocetine would be a helpful adjunct to use of benzodiazepines.

      The interaction is supported by preliminary,weak, fragmentary, and/or contradictory scientific evidence.
    • Oxazepam

      In a preliminary trial, an extract of periwinkle called vinpocetine was shown to produce minor improvements in short-term memory among people taking flunitrazepam, a benzodiazepine.26 Further study is needed to determine if vinpocetine would be a helpful adjunct to use of benzodiazepines, or oxazepam specifically.

      The interaction is supported by preliminary,weak, fragmentary, and/or contradictory scientific evidence.
    • Temazepam

      In a preliminary trial, an extract of periwinkle called vinpocetine was shown to produce minor improvements in short-term memory among people taking flunitrazepam, a benzodiazepine.27 Further study is needed to determine if vinpocetine would be a helpful adjunct to use of benzodiazepines.

      The interaction is supported by preliminary,weak, fragmentary, and/or contradictory scientific evidence.
    • Triazolam

      In a preliminary trial, an extract of periwinkle called vinpocetine was shown to produce minor improvements in short-term memory among people taking flunitrazepam, a benzodiazepine.28 Further study is needed to determine if vinpocetine would be a helpful adjunct to use of benzodiazepines, or triazolam specifically.

      The interaction is supported by preliminary,weak, fragmentary, and/or contradictory scientific evidence.

    Reduces Effectiveness

    • none

    Potential Negative Interaction

    • none

    Explanation Required

    • none

    The Drug-Nutrient Interactions table may not include every possible interaction. Taking medicines with meals, on an empty stomach, or with alcohol may influence their effects. For details, refer to the manufacturers? package information as these are not covered in this table. If you take medications, always discuss the potential risks and benefits of adding a supplement with your doctor or pharmacist.

    Side Effects

    Side Effects

    Studies on vinpocetine report no serious side effects with amounts up to 60 mg per day.29

    References

    1. Hindmarch I, Fuchs HH, Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol 1991;6:31?43.

    2. Balestreri R, Fontana L, Astengo F. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriatr Soc 1987;35:425?30.

    3. Peruzza M, DeJacobis M. A double-blind placebo controlled evaluation of the efficacy and safety of vinpocetine in the treatment of patients with chronic vascular or degenerative senile cerebral dysfunction. Adv Ther 1986;3:201?9.

    4. Manconi E, Binaghi F, Pitzus F. A double-blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenerative origin. Curr Ther Res Clin Exp1986;30:702?709.

    5. Thal LJ, Salmon DP, Lasker B, et al. The safety and lack of efficacy of vinpocetine in Alzheimer's disease. J Am Geriatr Soc 1989;37:515?20.

    6. Gulyas B, Bonoczk P, Vas A, et al. [The effect of a single-dose intravenous vinpocetine on brain metabolism in patients with ischemic stroke.] Orv Hetil2001;142:443?9 [in Hungarian].

    7. Szakall S, Boros I, Balkay L, et al. Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: a PET study. J Neuroimaging1998;8:197?204.

    8. Feigin VL, Doronin BM, Popova TF, et al. Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial. Eur J Neurol2001;8:81?5.

    9. Bereczki D, Fekete I. A systematic review of vinpocetine therapy in acute ischaemic stroke. Eur J Clin Pharmacol 1999;55:349-52 [review].

    10. Bereczki D, Fekete I. Vinpocetine for acute ischaemic stroke. Cochrane Database Sys Rev2000;2:CD000480.

    11. Truss MC, Stief CG, Uckert S, et al. Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World J Urol 2000;18:439-43.

    12. Truss MC, Stief CG, Uckert S, et al. Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol 2001;19:344-50 [review].

    13. Taiji H, Kanzaki J. Clinical study of vinpocetine in the treatment of vertigo. Jpn Pharmacol and Ther (Japan) 1986;14:577?89.

    14. Ribari O, Zelen B, Kollar B. Ethyl apovincaminate in the treatment of sensorineural impairment of hearing. Arzneimittelforschung 1976;26:1977?80.

    15. Brooser G, Anda L, Doman J. Preliminary report on the use of ethyl apovincaminate in affections of the eyeground. Arzneimittelforschung 1976;26:1973?5.

    16. Lohmann A, Dingler E, Sommer W, et al. Bioavailability of vinpocetine and interference of the time of application with food intake. Arzneimittelforschung 1992;42:914?7.

    17. Osawa M, Maruyama S. Effects of TCV-3B (vinpocetine) on blood viscosity in ischemic cerebrovascular diseases. Ther Hung 1985;33:7?12.

    18. Hitzenberger G, Sommer W, Grandt R. Influence of vinpocetine on warfarin-induced inhibition of coagulation. Int J Clin Pharmacol Ther Toxicol1990;28:323?8.

    19. Bhatti JZ, Hindmarch I. Vinpocetine effects on cognitive impairments produced by flunitrazepam. Int Clin Psychopharmacol 1987;2:325?31.

    20. Bhatti JZ, Hindmarch I. Vinpocetine effects on cognitive impairments produced by flunitrazepam. Int Clin Psychopharmacol 1987;2:325?31.

    21. Bhatti JZ, Hindmarch I. Vinpocetine effects on cognitive impairments produced by flunitrazepam. Int Clin Psychopharmacol 1987;2:325?31.

    22. Bhatti JZ, Hindmarch I. Vinpocetine effects on cognitive impairments produced by flunitrazepam. Int Clin Psychopharmacol 1987;2:325?31.

    23. Bhatti JZ, Hindmarch I. Vinpocetine effects on cognitive impairments produced by flunitrazepam. Int Clin Psychopharmacol 1987;2:325?31.

    24. Bhatti JZ, Hindmarch I. Vinpocetine effects on cognitive impairments produced by flunitrazepam. Int Clin Psychopharmacol 1987;2:325?31.

    25. Bhatti JZ, Hindmarch I. Vinpocetine effects on cognitive impairments produced by flunitrazepam. Int Clin Psychopharmacol 1987;2:325?31.

    26. Bhatti JZ, Hindmarch I. Vinpocetine effects on cognitive impairments produced by flunitrazepam. Int Clin Psychopharmacol 1987;2:325?31.

    27. Bhatti JZ, Hindmarch I. Vinpocetine effects on cognitive impairments produced by flunitrazepam. Int Clin Psychopharmacol 1987;2:325?31.

    28. Bhatti JZ, Hindmarch I. Vinpocetine effects on cognitive impairments produced by flunitrazepam. Int Clin Psychopharmacol 1987;2:325?31.

    29. Hindmarch I, Fuchs HH, Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol1991;6:31?43.

    This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.

    Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.